-

Blood Science Update |Pre-Transplantation KMT2A-PTD Levels Predict Relapse in AML After Haploidentical HSCT
Study Design and Methods This single-center retrospective study analyzed 64 AML patients with KMT2A-PTD positivity at diagnosis who underwent HID HSCT between April 2016 and December 2020. Based on their…
-

Blood Science Update|γδ T Cells in Hematological Malignancies: Mechanisms and Therapeutic Strategies
Study Focus and Methods The authors conducted a comprehensive synthesis of existing literature, experimental data, and ongoing clinical trials to evaluate the roles of γδ T cell subsets in antitumor…
-

CUDA Yanqi Lake Meeting | Prof. Nianzeng Xing: Advancing Urology in China Through Multidisciplinary Collaboration
From April 11 to 13, 2025, the 5th Chinese Urological Doctor Association Yanqi Lake Meeting—jointly organized by the Chinese Medical Doctor Association and Chinese Urological Doctor Association—was successfully held in Beijing. The event brought together prominent experts from across the country to explore the future of urology in China. UroStream invited Professor Nianzeng Xing, President…
-

Blood Science Update|In Vitro Erythropoiesis: The Emerging Potential of Induced Pluripotent Stem Cells (iPSCs)
Despite over 100 million units of blood being donated annually, supply remains insufficient, particularly for patients with chronic conditions or in crisis settings. Alloimmunization and blood group incompatibilities further constrain transfusion efficacy. In response, researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate red blood cells (RBCs) in vitro as a…
-

Blood Science Update|Enhancing Hemophilia A Gene Therapy: Strategic F8 Deletions in AAV8 Vectors
Hemophilia A is a chronic bleeding disorder resulting from a deficiency in coagulation factor VIII (F8). Current treatment strategies rely on frequent F8 replacement therapy, which is limited by its short half-life, high cost, and the risk of inhibitor development. Gene therapy using adeno-associated virus serotype 8 (AAV8) has emerged as a promising modality, offering…
-

New Hope for HR+/HER2– Advanced Breast Cancer: postMONARCH Trial Results
Published on December 18, 2024 in the Journal of Clinical Oncology, the phase III postMONARCH trial presents compelling data on abemaciclib + fulvestrant for patients with advanced breast cancer who…
-

Reducing SOS Risk in R/R B-ALL Patients Undergoing Stem Cell Transplantation: A Collaborative Study
At the 2024 ASH Annual Meeting, Dr. Syed Osman Ahmed contributed to a study investigating the incidence of sinusoidal obstruction syndrome (SOS) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia…
-

ASCO 2024 | Breakthrough in Combined Therapy with Adebrelimab: Ushering in a New Era for Small Cell Lung Cancer Treatment in China
A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to…